# SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer

> **NCT01583361** · PHASE3 · UNKNOWN · sponsor: **Lin Chen** · enrollment: 772 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin+S-1
- **DRUG:** Adjuvant Oxaliplatin/S-1（SOX）

## Key facts

- **NCT ID:** NCT01583361
- **Lead sponsor:** Lin Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2014-09
- **Final completion:** 2017-01
- **Target enrollment:** 772 (ESTIMATED)
- **Last updated:** 2012-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583361, "SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01583361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*